Related by context. All words. (Click for frequent words.) 69 leukemia AML 68 lupus nephritis 68 lymphoma CTCL 67 cutaneous T cell 66 non metastatic osteosarcoma 66 cell lymphoma CTCL 66 diabetic nephropathy 66 tanespimycin 66 Myelofibrosis 65 myeloproliferative disorders 65 hematologic malignancies 65 myelodysplastic syndrome MDS 65 ruxolitinib 65 relapsed multiple myeloma 65 leukemia ALL 65 INCB# [002] 64 Hodgkin lymphoma NHL 64 refractory AML 64 solid tumors 64 relapsed refractory multiple myeloma 64 myelodysplastic syndromes 64 ponatinib 64 myelodysplastic syndromes MDS 64 relapsing remitting multiple sclerosis 64 Atiprimod 64 multiple myeloma 64 myeloproliferative diseases 63 phase IIb clinical 63 renal cell carcinoma 63 polycythemia vera essential thrombocythemia 63 idiopathic pulmonary fibrosis IPF 63 myelofibrosis MF 63 indolent NHL 63 hypercalcemia 63 essential thrombocythemia 63 JAK1 63 refractory Hodgkin lymphoma 63 hematologic disorders 63 cutaneous T 63 JAK inhibitor 62 chronic lymphocytic leukemia CLL 62 systemic lupus erythematosus 62 relapsed refractory 62 leukemia CLL 62 metastatic renal cell carcinoma 62 alvespimycin 62 Xanafide 62 heterozygous FH 62 Acute Myelogenous Leukemia AML 62 aHUS 62 PEG PAL 62 gastrointestinal stromal tumors 62 obatoclax 62 neuroendocrine tumors 62 diabetic gastroparesis 62 INCB# [003] 62 heavily pretreated 62 acute myelogenous leukemia AML 62 metastatic melanoma 62 refractory gout 61 Evoltra ® 61 PNP inhibitor 61 lomitapide 61 tafamidis 61 metastatic renal cell 61 HeFH 61 Annamycin 61 myeloproliferative neoplasms 61 OHR/AVR# 61 talactoferrin 61 HuMax CD4 61 homozygous familial hypercholesterolemia 61 Azedra 61 hematological cancers 61 purpura ITP 61 mRCC 61 eltrombopag 61 azacitidine 61 recurrent glioblastoma 61 Tasimelteon 61 refractory acute myeloid 61 sapacitabine 61 OvaRex ® MAb 61 eculizumab 61 recurrent glioblastoma multiforme 61 Phase #b/#a clinical 61 glioblastoma 61 pancreatic NET 61 hypereosinophilic syndrome 61 Acute Myeloid Leukemia AML 61 gastrointestinal stromal tumor GIST 61 myelofibrosis polycythemia vera 61 TELINTRA 61 Amrubicin 61 bone metastases 61 rALLy clinical trial 61 HspE7 61 medullary thyroid cancer 61 diabetic neuropathic pain 60 Phase IIb trials 60 AA amyloidosis 60 hypoparathyroidism 60 pemphigus vulgaris 60 disease modifying 60 Phenoptin 60 polycythemia vera PV 60 Zerenex 60 Marqibo 60 transplantation HCT 60 advanced carcinoid 60 AEG# 60 INCB# [001] 60 CTAP# Capsules 60 acute myeloid leukemia 60 JAK2 inhibitor 60 vandetanib 60 Ph + ALL 60 pseudobulbar affect PBA 60 infantile spasms 60 mixed dyslipidemia 60 chronic myeloid leukemia CML 60 pediatric acute lymphoblastic 60 refractory angina 60 carcinoid tumors 60 hematological malignancies 60 hereditary angioedema 60 Archexin 60 Myelodysplastic syndromes MDS 60 chronic eosinophilic leukemia 60 maribavir 60 blinatumomab 60 refractory CLL 60 Amigal 60 relapsed leukemia 60 forodesine 60 von Willebrand disease 60 histone deacetylase HDAC inhibitor 60 systemic anaplastic large 60 IV melanoma 60 IV NSCLC 60 hyperoxaluria 60 relapsed SCLC 60 systemic lupus erythematosus SLE 60 relapsing remitting 60 Cutaneous T 60 Ceflatonin 60 belinostat 60 phase IIa clinical 60 HoFH 60 Bezielle 60 Plicera 60 lumiliximab 60 imatinib resistant 60 polycythemia vera 60 ELACYT 60 metastatic lung cancer 60 gastrointestinal stromal tumors GIST 60 Ilaris 60 sJIA 60 TRIOLEX 60 voreloxin 60 tumor lysis syndrome 60 gastrointestinal stromal tumor 60 Acute myeloid leukemia 60 EFAPROXYN 60 Diabetic Macular Edema 59 phase IIb trial 59 ruboxistaurin 59 IRX 2 59 generation purine nucleoside 59 hormone refractory prostate cancer 59 essential thrombocythemia ET 59 refractory chronic lymphocytic 59 dexanabinol 59 oxypurinol 59 OMAPRO 59 NYHA Class II 59 BrachySil TM 59 Panzem R 59 GRN#L 59 cell lymphoma ALCL 59 Dacogen injection 59 dirucotide 59 subependymal giant cell 59 ADHF 59 peritumoral brain edema 59 PRT# 59 receptor tyrosine kinase inhibitor 59 EOquin 59 acute GvHD 59 vidofludimus 59 opioid induced constipation 59 Gleevec resistant 59 PXD# 59 PEGylated interferon beta 1a 59 GvHD 59 castrate resistant prostate cancer 59 chronic myeloid 59 Myelodysplastic Syndrome MDS 59 metastatic malignant melanoma 59 anti angiogenic agents 59 superficial bladder cancer 59 familial amyloidotic polyneuropathy FAP 59 Troxatyl 59 invasive candidiasis 59 Bortezomib 59 dasatinib Sprycel ® 59 OncoVEX GM CSF 59 pan HDAC inhibitor 59 YONDELIS 59 imatinib mesylate 59 hematologic 59 PAOD 59 adverse cytogenetics 59 Cloretazine 59 secondary hyperparathyroidism 59 Phase 2a clinical 59 glioblastoma multiforme GBM 59 metastatic malignant 59 KIACTA ™ 59 remission induction 59 Chronic lymphocytic leukemia 59 mycosis fungoides 59 chronic plaque psoriasis 59 BAY #-# 59 curative therapy 59 oral mucositis 59 registrational trial 59 hepatic encephalopathy 59 tuberous sclerosis TS 59 alvimopan 59 Soliris TM eculizumab 59 BRAF inhibitor 59 Behcet uveitis 59 recurrent GBM 59 diabetic macular edema 59 anaplastic thyroid cancer 59 Bronchiectasis 59 pouchitis 59 PRTX 59 TBC# 59 Hepatocellular Carcinoma HCC 59 fibrotic disease 59 chronic lymphocytic leukemia 59 rALLy 59 INC# 59 Phase IIa trial 59 post herpetic neuralgia 59 chronic ITP 59 Proxinium TM 59 elotuzumab 59 CA4P 59 retinal vein occlusion 59 pancreatic adenocarcinoma 59 AQ4N 59 leukemia APL 59 metastatic RCC 59 anti leukemic 58 Ceflatonin R 58 multiple myeloma MM 58 glufosfamide 58 acute lymphoblastic leukemia 58 MPS VI 58 atypical hemolytic uremic syndrome 58 panobinostat 58 non alcoholic steatohepatitis 58 chronic thromboembolic pulmonary 58 radiation sensitizer 58 tesetaxel 58 pulmonary arterial hypertension 58 ara C 58 familial hypercholesterolemia FH 58 Glioblastoma Multiforme 58 Zarnestra 58 Phase 2b clinical 58 forodesine hydrochloride 58 metastatic kidney 58 clofarabine 58 leukemia CML 58 teriflunomide 58 cytogenetic responses 58 PANVAC VF 58 liver metastases 58 Pseudomonas aeruginosa infections 58 ganetespib 58 chronic immune thrombocytopenic 58 acute myeloid leukemia AML 58 Chronic Myeloid Leukemia CML 58 registrational 58 Fx #A 58 dasatinib 58 chronic myelogenous leukemia CML 58 Serdaxin 58 Follicular lymphoma 58 sunitinib malate 58 NSCLC 58 Fibrillex TM 58 acute leukemias 58 AP# [003] 58 MPS IVA 58 pralatrexate 58 pheochromocytoma 58 TNF antagonist 58 painful diabetic neuropathy 58 deferiprone 58 inhibitor RG# 58 generalized seizures 58 MyVax R 58 TREANDA 58 clinical endpoints 58 uveitis 58 Phase IIa clinical 58 Campath alemtuzumab 58 graft dysfunction 58 Tamibarotene 58 neurogenic orthostatic hypotension 58 iron overload 58 FOLOTYN ® 58 RG# [001] 58 Safinamide 58 sodium glucose cotransporter 58 relapsing multiple sclerosis 58 CTCL 58 Mipomersen 58 castration resistant prostate cancer 58 severe oral mucositis 58 tumors GIST 58 sorafenib Nexavar 58 carcinoid syndrome 58 hepatocellular cancer 58 B CLL 58 Leber Hereditary Optic Neuropathy 58 amrubicin 58 Personalized Immunotherapy 58 Hodgkin lymphoma HL 58 juvenile myelomonocytic leukemia 58 Phase Ib 58 Ophena TM 58 tyrosine kinase inhibitors 58 reslizumab 58 immune thrombocytopenic purpura ITP 58 biologic therapy 58 oral ridaforolimus 58 severe sepsis 58 Cushing Syndrome 58 gemcitabine Gemzar ® 58 postherpetic neuralgia 58 otelixizumab 58 chronic GVHD 58 riociguat 58 severe hypercholesterolemia 58 nilotinib 58 IMA# 58 cetuximab Erbitux R 58 lymphocytic leukemia 58 unresectable 58 noninfectious uveitis 58 LEP ETU 58 epithelial tumors 58 platinum refractory 58 acute decompensated heart 58 Doxil ® 58 chronic myocardial ischemia 58 liposomal formulation 58 Uricase PEG 58 bendamustine 58 schizophrenia CIAS 58 hepatic encephalopathy HE 58 metastatic uveal melanoma 58 tyrosine kinase inhibitors TKIs 58 VEGF inhibitors 58 CD3 monoclonal antibody 58 refractory cutaneous T 58 biliary tract cancer 58 metastatic GIST 58 CEQ# 58 Ambrisentan 58 stage IIIB 58 herpetic keratitis 58 IL# PE#QQR 58 humanized anti 58 TG# [003] 58 systemic lupus 58 Clolar 58 targeted radiotherapeutic 58 Laquinimod 58 elacytarabine 58 picoplatin 58 idiopathic thrombocytopenic purpura ITP 58 SinuNase 58 pivotal Phase III 58 vWD 58 myeloproliferative disorder 58 cardiac toxicity 58 non splenectomized 58 relapsed ovarian cancer 58 myelosuppression 58 hyperuricemia 58 SHPT 58 LHRH antagonists 58 Follicular Lymphoma 58 metaglidasen 58 acute leukemia 58 homozygous FH 58 myeloid metaplasia 58 Primary IGFD 58 FavId 58 basal cell carcinoma BCC 58 BZL# 58 refractory multiple myeloma 58 Symadex 58 Cannabinor 58 LHON 58 cytopenias 58 Chronic Myeloid Leukemia 58 Acute myeloid leukemia AML 58 recurrent NSCLC 57 catheter occlusion 57 OvaRex R 57 L Annamycin 57 MyVax ® 57 Rituxan rituximab 57 malignant pleural mesothelioma 57 CD# antibody [001] 57 CLL 57 CBLC# 57 R#/MEM # 57 zanolimumab 57 anterior uveitis 57 ZYBRESTAT 57 atacicept 57 relapsed AML 57 axitinib 57 hepatocellular carcinoma 57 acetonide FA 57 metastatic colorectal cancer 57 pancreatic carcinoma 57 Phase 2a trial 57 eosinophilic asthma 57 tiapamil 57 Alocrest 57 palifosfamide 57 TACI Ig 57 refractory metastatic colorectal cancer 57 CYT# potent vascular disrupting 57 OMNARIS HFA 57 Seliciclib 57 lintuzumab SGN 57 Lixivaptan 57 chronic ITP patients 57 fallopian tube carcinoma 57 Elagolix 57 SUTENT 57 pulmonary hypertension PH 57 Omacetaxine 57 lupus renal disease 57 Allovectin 7 57 Azedra TM 57 Corlux 57 HER2 positive breast cancer 57 huN# DM1 57 Friedreich Ataxia FRDA 57 neuroendocrine cancers 57 imatinib Gleevec ® 57 confirmatory Phase III 57 primary generalized tonic 57 Sym# 57 octreotide 57 rindopepimut 57 proliferative diabetic retinopathy 57 colorectal liver metastases 57 L BLP# 57 MGd 57 chronic renal failure 57 bardoxolone 57 Chemophase 57 chronic idiopathic thrombocytopenic purpura 57 Alemtuzumab 57 follicular lymphoma 57 ALN PCS 57 romidepsin 57 MELAS 57 nonalcoholic steatohepatitis NASH 57 CMV disease 57 refractory NSCLC 57 gastrointestinal mucositis 57 tivozanib 57 metastatic sarcomas 57 Microplasmin 57 Firazyr 57 nephrotoxicity 57 antitumor activity 57 Evoltra TM 57 bosutinib 57 sodium thiosulfate STS 57 intravesical therapy 57 Thrombocytopenia 57 Severe Primary IGFD 57 vertebral compression fractures 57 hormone refractory 57 peripheral sensory neuropathy 57 idiopathic thrombocytopenic purpura 57 SinuNase TM 57 CIMZIA ™ 57 ILUVIEN ® 57 T2DM 57 RSR# 57 Intravenous CP 57 idiopathic myelofibrosis 57 GVHD 57 myelodysplastic myeloproliferative diseases 57 mTOR inhibitor 57 haematological malignancies 57 Fabry Disease 57 ADVEXIN 57 vascular disrupting agent 57 Phase #/#a trial 57 CRVO 57 Romidepsin 57 SJIA 57 Sezary syndrome 57 decitabine 57 carcinoid 57 Chronic Lymphocytic Leukemia CLL 57 Major Depressive Disorder MDD 57 GALNS 57 orally administered inhibitor 57 hereditary deficiency 57 Glioblastoma multiforme GBM 57 acute myeloid 57 pancreatic insufficiency 57 PNH patients 57 SNT MC# 57 octreotide implant 57 haematological cancers 57 ThermoDox ® 57 cetuximab Erbitux ® 57 PS# [001] 57 investigational monoclonal antibody 57 HGS ETR1 57 Kit CD# positive 57 Factor VIIa 57 dopaminergic therapy 57 hyperphenylalaninemia HPA due 57 Myelodysplastic Syndrome 57 docetaxel chemotherapy 57 KRN# 57 metastatic castration resistant 57 Azixa 57 Hsp# inhibition 57 Lupus Nephritis 57 Sprycel dasatinib 57 orBec R 57 Alessandro Riva 57 ATryn R 57 ADPKD 57 enzastaurin 57 Pirfenidone 57 tamibarotene 57 Phase Ib study 57 AEGR 57 invasive aspergillosis 57 Tyrima 57 hematologic toxicity 57 Telintra 57 ALN TTR# 57 HQK 57 malignant pheochromocytoma 57 mifamurtide 57 MBP# [001] 57 uncontrolled seizures 57 cytotoxic chemotherapy 57 ofatumumab 57 Dapagliflozin 57 systemic fungal infections 57 immune idiopathic thrombocytopenic 57 myelodysplasia 57 Traficet EN 57 active ankylosing spondylitis 57 cintredekin besudotox 57 neuropathic pain metabolic diseases 57 hereditary antithrombin deficiency 57 darusentan 57 hyperkalemia 57 chemotherapy induced neutropenia 57 romiplostim 57 mipomersen 57 constipation OIC 57 cannabinor 57 CABP 57 myelodysplastic syndrome 57 cangrelor 57 Systemic Lupus Erythematosus SLE 57 efficacy endpoint 57 EVIZON 57 HP Acthar Gel repository 57 stage IIIb 57 pulmonary arterial hypertension PAH 57 complete remissions 57 Asentar 57 tolvaptan 57 candidemia 57 drug ISA# 57 Spiro Rombotis President 57 dasatinib Sprycel 57 VAPRISOL 57 visilizumab 57 Friedreich ataxia 57 FOLOTYN 57 hyperphosphatemia 57 Pulmonary Arterial Hypertension PAH 57 davunetide 57 targeted radiotherapeutics 57 ALN TTR 57 Revimmune 57 oral prodrug 56 metastatic gastric 56 papillary renal cell carcinoma 56 Treanda 56 bosentan 56 hematologic cancers 56 sarcomas 56 relapsed MM 56 6R BH4 56 metastatic cancers 56 chronic gout 56 Pimavanserin 56 Li Fraumeni Syndrome 56 tramiprosate 56 malignancies 56 hypophosphatasia 56 Torisel 56 skeletal metastases 56 IBS C 56 Phase IIb clinical trials 56 allogeneic bone marrow 56 haematologic malignancies 56 hepatorenal syndrome 56 Nexavar sorafenib 56 Benlysta belimumab 56 INT# [002] 56 dyslipidemia 56 TKIs 56 huC# DM4 56 IV metastatic melanoma 56 metastatic bladder 56 myeloid 56 rNAPc2 56 resistant ovarian cancer 56 MYLOTARG 56 Phase 2b trial 56 Brentuximab Vedotin SGN 56 canakinumab 56 OPAXIO 56 pancreatic neuroendocrine tumors 56 recurrent glioma 56 opioid induced constipation OIC 56 dose limiting toxicities 56 Hurler syndrome 56 pertuzumab 56 paroxysmal nocturnal hemoglobinuria PNH 56 TYZEKA 56 AA Amyloidosis 56 monoclonal antibody therapies 56 bevacizumab Avastin ® 56 follicular NHL 56 depsipeptide 56 EOquin TM 56 investigational compounds 56 Familial Adenomatous Polyposis FAP 56 Hydroxyurea 56 Phase IIb trial 56 induced macular edema 56 Tavocept 56 Sudhir Agrawal D.Phil 56 NPSP# 56 advanced metastatic renal 56 VitiGam 56 geographic atrophy 56 ATIR 56 TTR amyloidosis 56 ThermoDox R 56 AAG geldanamycin analog 56 psoriasis psoriatic arthritis 56 fibromyalgia syndrome 56 anti angiogenic therapy 56 Vicinium TM 56 cardio renal 56 Solazed TM 56 dacetuzumab 56 trial evaluating PRX# 56 renin inhibitor 56 Actemra tocilizumab 56 CoFactor 56 including eniluracil ADH 56 CCR9 antagonist 56 brain metastases 56 Huntexil 56 terlipressin 56 apremilast 56 uric acid lowering 56 IMGN# 56 vascular disrupting agents 56 levodopa therapy 56 zalutumumab 56 chronic granulomatous disease 56 steroid refractory 56 intravenous cyclophosphamide 56 complement inhibitor eculizumab 56 ATTR PN 56 familial hypercholesterolemia 56 AVONEX ® 56 Cimzia TM 56 autoantibody positive 56 Toxicities 56 2 methoxyestradiol 56 dimebon 56 posaconazole 56 Phase III clinical trials 56 Octreolin 56 Deferiprone 56 allogeneic stem cell 56 post herpetic neuralgia PHN 56 Nuvion 56 mTOR inhibitors 56 MAGE A3 ASCI 56 Perifosine 56 immune thrombocytopenic purpura 56 leukoencephalopathy 56 diabetic macular edema DME 56 soft tissue sarcomas 56 sunitinib 56 adrenal insufficiency 56 Gaucher Disease 56 haematologic 56 hematological malignancy 56 relapsing MS 56 TORISEL 56 cardiac dysfunction 56 lucinactant 56 atypical Hemolytic Uremic Syndrome 56 palifermin 56 erlotinib Tarceva 56 Virulizin ® 56 bardoxolone methyl 56 diabetes mellitus T2DM 56 juvenile idiopathic arthritis 56 xanthine oxidase inhibitor 56 failure ADHF 56 prGCD 56 daclizumab 56 RPLS 56 grade glioma 56 Genasense ® oblimersen 56 Pivotal Phase III 56 ATIR TM 56 Idiopathic Pulmonary Fibrosis IPF 56 Zavesca 56 hematological diseases 56 measurable tumor regressions 56 palliation 56 systemic ALCL 56 BENLYSTA ® 56 PRX # 56 SNT-MC#/idebenone 56 Clofarabine 56 hepatocellular carcinoma HCC 56 Epratuzumab 56 davunetide intranasal AL 56 liprotamase 56 Chronic Lymphocytic Leukemia 56 eniluracil 56 GISTs 56 investigational therapies 56 NATRECOR ® 56 rheumatoid arthritis psoriatic arthritis 56 unresectable tumors 56 Friedreich Ataxia 56 Icatibant 56 vinorelbine 56 metastatic hormone refractory 56 vaso occlusive crisis 56 cardiogenic shock 56 dextofisopam 56 DDP# 56 cancer cachexia 56 ProSavin 56 inhaled liposomal ciprofloxacin 56 DXL# 56 Panzem R NCD 56 Pemetrexed 56 perifosine 56 Aplidin 56 selective modulator 56 HuLuc# 56 prostate cancer CRPC 56 LEUKINE 56 standard chemotherapy regimens 56 Bicifadine 56 ACCLAIM trial 56 dexpramipexole 56 opioid induced bowel dysfunction 56 acute mania 56 MKC# MT 56 pediatric bipolar disorder 56 LAF# 56 CYT# 56 novel VDA molecule 56 ANCHOR trial 56 medulloblastoma 56 lymphomas 56 Avanafil 56 chorea associated 56 erythematosus SLE 56 refractory epilepsy 56 Zytiga 56 Natalizumab 56 investigational drug 56 grade cervical intraepithelial 56 progressive neurodegenerative disorder 56 prostate cancer HRPC 56 Glioblastoma Multiforme GBM 56 tubulin inhibitor 56 Prestara 56 Pivotal Phase 56 Onrigin 56 cirrhosis liver failure 56 PsA 56 Xyfid TM 56 juvenile idiopathic arthritis JIA 56 relapsed CLL 56 posterior uveitis 56 astrocytoma 56 Viprinex 56 IPLEX 56 Insegia 56 relapsing remitting MS RRMS 56 metastatic CRC 56 Zenvia ™ 56 adult chronic ITP 56 Glioblastoma 56 Phase Ib clinical 56 dose cohorts 56 vorinostat 56 pancytopenia 56 astrocytomas 56 postoperative ileus POI 56 nephropathic cystinosis 56 primary hypercholesterolemia 56 degenerative retinal diseases 56 lintuzumab 56 Eltrombopag 56 SUTENT ® 56 prostate cancer mCRPC 56 EGFR inhibitors 56 pazopanib 56 thrombotic complications 56 Lennox Gastaut syndrome 56 novel histone deacetylase 56 ischemic cardiomyopathy 56 esophageal candidiasis 56 Folotyn 56 SILENOR TM 56 allograft rejection 56 modified glutathione analog 56 systemic lupus erythematosus lupus 56 relapsed Acute Myeloid 56 Gleevec imatinib 56 monotherapy 56 HuMax CD# 56 GW# [003] 56 imatinib Gleevec 56 PEGylated Fab fragment 56 hypertriglyceridemia 56 imatinib therapy 56 hereditary angioedema HAE 56 Chronic lymphocytic leukemia CLL 56 Jevtana 56 systolic hypertension 56 angiogenesis inhibitor 56 IAP inhibitors 56 AGILECT ® 56 gout flares 56 interventional therapies 55 ISTODAX 55 neurodegenerative disorder 55 erlotinib Tarceva ® 55 symptomatic neurogenic orthostatic hypotension 55 efaproxiral 55 trabectedin 55 SUPPRELIN R LA 55 Zingo TM 55 brivaracetam 55 Anavex #-# 55 pulmonary exacerbations 55 grade gliomas 55 alogliptin 55 relapsed GBM 55 T1DM 55 rFVIIIFc 55 rufinamide 55 metastatic cancer 55 Host Disease GvHD 55 Voreloxin 55 Ph.D. Targacept 55 heavily pretreated patients 55 placebo controlled clinical 55 calcineurin inhibitors 55 non Hodgkin lymphoma 55 cystinosis patients 55 critical limb ischemia 55 polyneuropathy CIDP 55 Ostarine 55 Revlimid lenalidomide 55 Romiplostim 55 Gel repository corticotropin injection 55 rFIXFc 55 NP2 Enkephalin 55 bucindolol 55 Phase III clinical 55 nonsmall cell lung cancer 55 Glioblastoma multiforme 55 Gleevec imatinib mesylate 55 KSP inhibitor 55 taxane refractory 55 diabetic retinopathy DR 55 Miraxion 55 ixabepilone 55 phase IIb 55 superficial basal cell carcinoma 55 fungoides 55 mGluR5 negative 55 BENLYSTA TM 55 SAI EGF 55 orBec 55 Entereg R 55 steroid refractory GvHD 55 cancer neuroendocrine tumor 55 atherothrombotic events 55 ACTEMRA 55 MOZOBIL 55 pirfenidone 55 tocilizumab 55 JMML 55 severe Primary IGFD 55 carfilzomib 55 chronic neuropathic pain 55 bafetinib 55 Pazopanib 55 interferon therapy 55 refractory chronic myeloid 55 ACTEMRA TM 55 iclaprim 55 metastatic bone 55 purpura 55 postherpetic neuralgia PHN 55 LymphoStat B belimumab 55 isoform selective 55 follicular lymphoma FL 55 pivotal Phase 55 vWF 55 Fibromyalgia Syndrome FMS 55 Leukine ® 55 Hedgehog Pathway Inhibitor 55 evaluating REVLIMID 55 receptor antagonist 55 JAK inhibitors 55 relapsing forms 55 previously untreated follicular 55 EVIZON TM 55 biologic therapies 55 fibrotic diseases 55 MYDICAR ® 55 MALT lymphoma 55 Alzhemed TM 55 psoriatic arthritis PsA 55 Darusentan 55 ATryn ® 55 acute myelogenous leukemia 55 pulmonary hypertension 55 neovascular AMD 55 locoregional 55 MPGN 55 favorable tolerability 55 neutropenia dehydration dyspnea 55 TTF Therapy 55 treprostinil 55 metastatic prostate cancer 55 Chronic myeloid leukemia CML 55 COPREXA 55 kinase inhibition 55 Acute Myelogenous Leukemia 55 keloid scarring 55 RRMS 55 metastatic disease 55 Cethromycin 55 Acute lymphoblastic leukemia 55 Vidaza azacitidine 55 Aviptadil